Pre-market hot trades in US stocks: Blue Gold pre-market down 15.35%; AppLovin pre-market down 10.43%

Pre-market Hot Trades in US Stocks Blue Gold, down 15.35% in pre-market, has no significant recent news. Trading is active with clear capital flow; considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. AppLovin, down 10.43% in pre-market. Based on recent news, On January 20, short-selling firm Culper Research released a report indicating that major shareholders of AppLovin are involved in money laundering, human trafficking, and illegal gambling, which may pose a delisting risk. This news triggered market panic, leading to a sharp decline in stock price. On January 20, market concerns about AppLovin's e-commerce business progress increased, especially during the sensitive period before the earnings report, leading to cautious investor sentiment and further pressure on the stock price. On January 20, AppLovin's advertising performance was poor, with data from Northbeam and BuiltWith showing declines in both advertising share and merchant domain numbers, raising market concerns about its growth prospects and putting pressure on the stock price. The logic for software stocks is weak, and capital is cautious ahead of earnings reports. Top Gainers in Pre-market US Stocks INVO Fertility, up 421.91% in pre-market, has no significant recent news. Trading is active with clear capital flow; considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Icon Energy, up 145.36% in pre-market, has no significant recent news. Trading is active with clear capital flow; considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. RAPT, up 63.53% in pre-market. Based on recent key news: On January 20, GSK announced the acquisition of RAPT Therapeutics for $2.2 billion, driving RAPT's stock price up 65% in pre-market. This acquisition will give GSK global rights to RAPT's experimental food allergy drug ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong. This move expands GSK's respiratory, immunology, and inflammation product lines. On January 20, GSK plans to pay $58 per share in cash, which represents a significant premium over RAPT's last closing price. This transaction is expected to be completed in the first quarter, further boosting market confidence in RAPT. On January 20, analysts rated GSK's stock as a moderate sell; nevertheless, RAPT's stock price surged significantly due to the acquisition news. Analysts believe GSK's price target is $38.69, indicating a 19.76% downside risk. The biotechnology industry is active in mergers and acquisitions, with clear capital inflow